Last reviewed · How we verify
NCT04305808
Characterization of Vaginal, Urinary and Fecal Microbiomes in Women with Recurrent Urinary Tract Infections
trial in Urinary Tract Infections in 40 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Hadassah Medical Organization |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 August 2021 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across Israel |
Conditions studied
- Urinary Tract Infections — all drugs for Urinary Tract Infections →
- Menopause — all drugs for Menopause →
Sponsor
Hadassah Medical Organization — full company profile →
Who can join
Eligibility, female only, with Urinary Tract Infections or Menopause. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objectives are to evaluate whether variations in vaginal and/or urinary and/or fecal microbiome predispose postmenopausal women to recurrent cystitis. This will be explored using comparison of microbiome profiles between those with recurrent UTI compared to age-matched women without recurrent UTI.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04305808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urinary Tract Infections
Currently open trials in the same condition.
- NCT06976125 — Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulat · NA · recruiting
- NCT06808451 — Diagnosis and Treatment of Urinary Tract Infection Using DNA Polymerase Chain Reaction Versus Urine Culture · NA · recruiting
- NCT07186465 — Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis · Phase 4 · recruiting
- NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
- NCT06715306 — Intravenous Versus Oral Treatment of the Main Acute Infections · NA · recruiting
Other Hadassah Medical Organization trials
Trials by the same sponsor.
- NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
- NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
- NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
- NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04305808 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
- Last refreshed: 19 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04305808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing